Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results

Witold Lasek, Adam Giermasz, Katarzyna Kuc, Anna Wańkowicz, Wojciech Feleszko, Jakub Goła̧b, Radosław Zagozdzon, Tomasz Stokłosa, Marek Jakóbisiak

Research output: Contribution to journalArticle

35 Citations (Scopus)

Abstract

The anti-tumor effects of actinomycin D (Act D) and recombinant human tumor necrosis factor (TNF)-α have been studied on 4 established murine tumor cell lines: MmB16 melanoma, Lewis lung (LL/2) carcinoma, LI sarcoma and LI210 leukemia. During short-term incubation (24 hr) Act D produced dose-dependent cytostatic/cytotoxic effects against MmB16, LL/2 and LI tumor cells but did not reduce the viability of these cells even at high concentration (10 μg/ml), below a threshold of 30-60%. However, LI210 leukemic cells were highly susceptible to Act D, and no viable cells were detected in cultures incubated with I μg/ml of Act D. TNF-α alone, when used under the same culture conditions, had only a negligible effect on all cell lines tested. However, the combination of this cytokine with Act D produced synergistic cytotoxic effects against MmB16, LL/2 and LI cells but not against LI21O leukemia cells, in an in vivo model of regional therapy in which tumor-bearing mice were treated with Act D and TNF-α, a correlation with in vitro results was observed. In mice bearing MmB16 melanoma, LL/2 carcinoma and LI sarcoma, the most potent anti-tumor effects were observed in mice treated with Act D and TNF-α together. This treatment led to a delay of tumor growth and induced complete tumor regression in some cases. On the contrary, TNF-α did not enhance the effect of Act D in mice injected with LI210 leukemia cells. Our results show that TNF-α can potentiate the anti-tumor effects of Act D against tumors weakly susceptible to Act D and may be a useful adjuvant to chemotherapy in the local treatment of neoplasia.

Original languageEnglish (US)
Pages (from-to)374-379
Number of pages6
JournalInternational Journal of Cancer
Volume66
Issue number3
StatePublished - May 3 1996
Externally publishedYes

Fingerprint

Dactinomycin
Tumor Necrosis Factor-alpha
Neoplasms
Leukemia
Sarcoma
Melanoma
Carcinoma
In Vitro Techniques
Cytostatic Agents
Adjuvant Chemotherapy
Tumor Cell Line
Cell Survival
Therapeutics
Cytokines
Cell Line
Lung
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice : Correlation between in vitro and in vivo results. / Lasek, Witold; Giermasz, Adam; Kuc, Katarzyna; Wańkowicz, Anna; Feleszko, Wojciech; Goła̧b, Jakub; Zagozdzon, Radosław; Stokłosa, Tomasz; Jakóbisiak, Marek.

In: International Journal of Cancer, Vol. 66, No. 3, 03.05.1996, p. 374-379.

Research output: Contribution to journalArticle

Lasek, W, Giermasz, A, Kuc, K, Wańkowicz, A, Feleszko, W, Goła̧b, J, Zagozdzon, R, Stokłosa, T & Jakóbisiak, M 1996, 'Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results', International Journal of Cancer, vol. 66, no. 3, pp. 374-379.
Lasek, Witold ; Giermasz, Adam ; Kuc, Katarzyna ; Wańkowicz, Anna ; Feleszko, Wojciech ; Goła̧b, Jakub ; Zagozdzon, Radosław ; Stokłosa, Tomasz ; Jakóbisiak, Marek. / Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice : Correlation between in vitro and in vivo results. In: International Journal of Cancer. 1996 ; Vol. 66, No. 3. pp. 374-379.
@article{76ed1d028cde42adb23c3d9403563f9d,
title = "Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice: Correlation between in vitro and in vivo results",
abstract = "The anti-tumor effects of actinomycin D (Act D) and recombinant human tumor necrosis factor (TNF)-α have been studied on 4 established murine tumor cell lines: MmB16 melanoma, Lewis lung (LL/2) carcinoma, LI sarcoma and LI210 leukemia. During short-term incubation (24 hr) Act D produced dose-dependent cytostatic/cytotoxic effects against MmB16, LL/2 and LI tumor cells but did not reduce the viability of these cells even at high concentration (10 μg/ml), below a threshold of 30-60{\%}. However, LI210 leukemic cells were highly susceptible to Act D, and no viable cells were detected in cultures incubated with I μg/ml of Act D. TNF-α alone, when used under the same culture conditions, had only a negligible effect on all cell lines tested. However, the combination of this cytokine with Act D produced synergistic cytotoxic effects against MmB16, LL/2 and LI cells but not against LI21O leukemia cells, in an in vivo model of regional therapy in which tumor-bearing mice were treated with Act D and TNF-α, a correlation with in vitro results was observed. In mice bearing MmB16 melanoma, LL/2 carcinoma and LI sarcoma, the most potent anti-tumor effects were observed in mice treated with Act D and TNF-α together. This treatment led to a delay of tumor growth and induced complete tumor regression in some cases. On the contrary, TNF-α did not enhance the effect of Act D in mice injected with LI210 leukemia cells. Our results show that TNF-α can potentiate the anti-tumor effects of Act D against tumors weakly susceptible to Act D and may be a useful adjuvant to chemotherapy in the local treatment of neoplasia.",
author = "Witold Lasek and Adam Giermasz and Katarzyna Kuc and Anna Wańkowicz and Wojciech Feleszko and Jakub Goła̧b and Radosław Zagozdzon and Tomasz Stokłosa and Marek Jak{\'o}bisiak",
year = "1996",
month = "5",
day = "3",
language = "English (US)",
volume = "66",
pages = "374--379",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Tentiation of the anti-tumor effect of actinomycin D by tumor necrosis factor α in mice

T2 - Correlation between in vitro and in vivo results

AU - Lasek, Witold

AU - Giermasz, Adam

AU - Kuc, Katarzyna

AU - Wańkowicz, Anna

AU - Feleszko, Wojciech

AU - Goła̧b, Jakub

AU - Zagozdzon, Radosław

AU - Stokłosa, Tomasz

AU - Jakóbisiak, Marek

PY - 1996/5/3

Y1 - 1996/5/3

N2 - The anti-tumor effects of actinomycin D (Act D) and recombinant human tumor necrosis factor (TNF)-α have been studied on 4 established murine tumor cell lines: MmB16 melanoma, Lewis lung (LL/2) carcinoma, LI sarcoma and LI210 leukemia. During short-term incubation (24 hr) Act D produced dose-dependent cytostatic/cytotoxic effects against MmB16, LL/2 and LI tumor cells but did not reduce the viability of these cells even at high concentration (10 μg/ml), below a threshold of 30-60%. However, LI210 leukemic cells were highly susceptible to Act D, and no viable cells were detected in cultures incubated with I μg/ml of Act D. TNF-α alone, when used under the same culture conditions, had only a negligible effect on all cell lines tested. However, the combination of this cytokine with Act D produced synergistic cytotoxic effects against MmB16, LL/2 and LI cells but not against LI21O leukemia cells, in an in vivo model of regional therapy in which tumor-bearing mice were treated with Act D and TNF-α, a correlation with in vitro results was observed. In mice bearing MmB16 melanoma, LL/2 carcinoma and LI sarcoma, the most potent anti-tumor effects were observed in mice treated with Act D and TNF-α together. This treatment led to a delay of tumor growth and induced complete tumor regression in some cases. On the contrary, TNF-α did not enhance the effect of Act D in mice injected with LI210 leukemia cells. Our results show that TNF-α can potentiate the anti-tumor effects of Act D against tumors weakly susceptible to Act D and may be a useful adjuvant to chemotherapy in the local treatment of neoplasia.

AB - The anti-tumor effects of actinomycin D (Act D) and recombinant human tumor necrosis factor (TNF)-α have been studied on 4 established murine tumor cell lines: MmB16 melanoma, Lewis lung (LL/2) carcinoma, LI sarcoma and LI210 leukemia. During short-term incubation (24 hr) Act D produced dose-dependent cytostatic/cytotoxic effects against MmB16, LL/2 and LI tumor cells but did not reduce the viability of these cells even at high concentration (10 μg/ml), below a threshold of 30-60%. However, LI210 leukemic cells were highly susceptible to Act D, and no viable cells were detected in cultures incubated with I μg/ml of Act D. TNF-α alone, when used under the same culture conditions, had only a negligible effect on all cell lines tested. However, the combination of this cytokine with Act D produced synergistic cytotoxic effects against MmB16, LL/2 and LI cells but not against LI21O leukemia cells, in an in vivo model of regional therapy in which tumor-bearing mice were treated with Act D and TNF-α, a correlation with in vitro results was observed. In mice bearing MmB16 melanoma, LL/2 carcinoma and LI sarcoma, the most potent anti-tumor effects were observed in mice treated with Act D and TNF-α together. This treatment led to a delay of tumor growth and induced complete tumor regression in some cases. On the contrary, TNF-α did not enhance the effect of Act D in mice injected with LI210 leukemia cells. Our results show that TNF-α can potentiate the anti-tumor effects of Act D against tumors weakly susceptible to Act D and may be a useful adjuvant to chemotherapy in the local treatment of neoplasia.

UR - http://www.scopus.com/inward/record.url?scp=0029900289&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029900289&partnerID=8YFLogxK

M3 - Article

C2 - 8621260

AN - SCOPUS:0029900289

VL - 66

SP - 374

EP - 379

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -